↓ Skip to Main Content
Thasso
Thasso the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs

search: thasso

Log in

Main Navigation

  • english
    • english
    • français
    • deutsch
    • italiano
    • español
    • português
  • thasso
  • thasso post
  • thasso toolbox
    • theragenomics: useful links
    • theragenomics: biomarkers
    • theragenomics: companion tests
    • theragenomics: drug labels with annotated information
    • theragenomics: drugs and genes
    • theragenomics: the world of alleles
    • theragenomics: allele-related guideline information
    • drug interactions
    • drug information
    • drug adverse reactions
    • drugs: risk evaluation and mitigation strategies (REMS)
    • theragenomics: videos
  • thasso academy
    • health authorities
    • patient & consumer health
    • public domain
      • Swiss Academy of Medical Sciences
      • EUPATI The European Patients’ Academy on Therapeutic Innovation
    • companies
    • products
    • about
  • thasso community
    • thasso: simple chat
    • thasso: video chat
    • theragenomics: survey at thasso
      • survey participants
    • forum
      • patient groups / subgroups
      • group
      • lounge
      • events
      • gallery
  • thasso: about
    • vision
    • background
    • the apomediary patient
    • contact
    • disclaimers
    • policies
  • donations
    • thasso – thank you
    • Donation Confirmation

Tag: Advanced Ovarian Cancer

Right in time for Christmas, FDA approved Ceftolozane/Tazobactam (Zerbaxa), Ombitasvir/Paritaprevir/Ritonavir co-packaged with Dasabuvir (Viekira Pak), and Olaparib (Lynparza)

By Joseph Gut - thasso Posted on December 21, 2014 Posted in New Drug Approval, Thasso Post Tagged with Advanced Ovarian Cancer, BRACAnalysis CDx Companion Test, Ceftolozane/Tazobactam (Zerbaxa), Chronic Hepatitis C Virus (HCV), Complicated Intra-Abdominal Infections (cIAI), Complicated Urinary Tract Infections (cUTI), Generating Antibiotic Incentives Now (GAIN), Germline BRCA Mutated (gBRCAm), Olaparib (Lynparza), Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir (Viekira Pak), Qualified Infectious Disease Product (QIDP), Thasso Post, Theragenomic Medicine

December 20, 2014 – Right in time for Christmas, the American Food & Drug Admininistration (FDA) on December 19 approved three significant new drugs, namely Ceftolozane/Tazobactam (Zerbaxa), Ombitasvir/Paritaprevir/Ritonavir co-packaged with Dasabuvir (Viekira Pak) and Olaparib (Lynparza), each of which represents …

Right in time for Christmas, FDA approved Ceftolozane/Tazobactam (Zerbaxa), Ombitasvir/Paritaprevir/Ritonavir co-packaged with Dasabuvir (Viekira Pak), and Olaparib (Lynparza) Read more »

Footer Menu

  • english
  • thasso
  • thasso post
  • thasso toolbox
  • thasso academy
  • thasso community
  • thasso: about
  • donations
Copyright © 2025 Thasso | Powered by Responsive Theme